Edaravone dexborneol in acute ischaemic stroke: an updated GRADE assessed systematic review and meta-analysis with trial sequential analysis
EDB produces a TSA-confirmed improvement in 90-day excellent functional recovery (mRS 0–1) and functional independence (mRS 0–2), but TSA could not confirm evidentiary sufficiency because the sequential boundary was assessable only at the earliest information fraction, so further corroboration is warranted.